Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S - American Depositary Shares
(NQ:
GMAB
)
20.31
+0.22 (+1.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S - American Depositary Shares
< Previous
1
2
3
4
5
6
7
Next >
NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals.
December 19, 2024
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued.
Via
Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:GMAB.
December 10, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase.
November 29, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals.
November 25, 2024
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued.
Via
Chartmill
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
November 18, 2024
NASDAQ:GMAB, a growth stock which is not overvalued.
Via
Chartmill
A Closer Look at 10 Analyst Recommendations For Genmab
November 08, 2024
Via
Benzinga
Preview: Genmab's Earnings
November 05, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
October 30, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
12 Analysts Have This To Say About Genmab
October 16, 2024
Via
Benzinga
NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
October 09, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
October 29, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
October 28, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive.
Via
Chartmill
NASDAQ:GMAB is an undervalued gem with solid fundamentals.
October 08, 2024
Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
NASDAQ:GMAB, a growth stock which is not overvalued.
October 07, 2024
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via
Chartmill
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 23, 2024
Via
Benzinga
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
September 17, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals.
Via
Chartmill
Expert Ratings For Genmab
September 09, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
September 03, 2024
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
August 26, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing.
Via
Chartmill
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
September 16, 2024
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Decoding 10 Analyst Evaluations For Genmab
August 20, 2024
Via
Benzinga
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
August 13, 2024
Via
Benzinga
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
August 08, 2024
GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
August 05, 2024
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...
Via
Benzinga
Exposures
COVID-19
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
August 05, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
What 8 Analyst Ratings Have To Say About Genmab
August 01, 2024
Via
Benzinga
What 8 Analyst Ratings Have To Say About Genmab
July 15, 2024
Via
Benzinga
NASDAQ:GMAB, an undervalued stock with good fundamentals.
July 01, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
August 05, 2024
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via
Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
July 15, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.